` UNCY (Unicycive Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

UNCY
vs
S&P 500

Over the past 12 months, UNCY has underperformed S&P 500, delivering a return of -16% compared to the S&P 500's +14% growth.

Stocks Performance
UNCY vs S&P 500

Loading
UNCY
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
UNCY vs S&P 500

Loading
UNCY
S&P 500
Difference
www.alphaspread.com

Performance By Year
UNCY vs S&P 500

Loading
UNCY
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Unicycive Therapeutics Inc vs Peers

S&P 500
UNCY
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Unicycive Therapeutics Inc
Glance View

Market Cap
119.5m USD
Industry
Biotechnology

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 9 full-time employees. The company went IPO on 2021-06-17. The firm is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.

UNCY Intrinsic Value
Not Available
Back to Top